Carisma Therapeutics nominates first lead candidate in Moderna collaboration

Carisma Therapeutics (CARM) announced the nomination of its first lead candidate under the collaboration with Moderna (MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma’s chimeric antigen receptor macrophage platform with Moderna’s messenger RNA and lipid nanoparticle technologies to generate and develop in vivo CAR-M therapeutics for oncology. Pre-clinical proof of concept data were recently presented at SITC 2023, demonstrating the feasibility, efficacy, and tolerability of the in vivo CAR-M platform.